IMC Chicago’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

IMC Chicago’s Portfolio BIB Stock Details BIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-22,406	Closed	-$1.08M	–	3300
2025 Q1	$1.08M	Buy	+22,406	New	+$1.2M	﹤0.01%	2226
2024 Q4	–	Sell	-22,868	Closed	-$1.46M	–	3147
2024 Q3	$1.46M	Buy	22,868 +11,019	+93%	+$711K	﹤0.01%	1851
2024 Q2	$702K	Buy	+11,849	New	+$656K	﹤0.01%	2148
2024 Q1	–	Sell	-42,674	Closed	-$2.43M	–	2345
2023 Q4	$2.43M	Buy	+42,674	New	+$2M	﹤0.01%	1142
2023 Q3	–	Sell	-14,247	Closed	-$741K	–	1589
2023 Q2	$741K	Sell	14,247 -29,997	-68%	-$1.65M	﹤0.01%	1121
2023 Q1	$2.4M	Buy	+44,244	New	+$2.5M	﹤0.01%	807

Other funds holding BIB

CIC

Chase Investment Counsel Charlottesville, Virginia $381M AUM 69.8% 1-Year Est. Return

WWM

Westwood Wealth Management Los Angeles, California $255M AUM 54.97% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

CIA

Capital Investment Advisors Atlanta, Georgia $6.84B AUM 17.28% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

TFA

Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

PSFG

Park Square Financial Group Roswell, Georgia $13.2M AUM 23.63% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

Garde Capital Seattle, Washington $1.67B AUM 13.9% 1-Year Est. Return

IMC Chicago's BIB Position: Q2 2025 in Review

IMC Chicago sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q2 2025, closing a stake of 22,406 shares — an estimated $1.08M sold.

IMC Chicago first reported a position in BIB in Q1 2023 and held it in 6 quarters. The position peaked at $2.43M in Q4 2023. 17 funds tracked by Wall St. Rank hold BIB as of Q2 2025.

IMC Chicago reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q2 2025 after selling out during the quarter.
IMC Chicago sold 22,406 ProShares Ultra NASDAQ Biotechnology shares in Q2 2025, an estimated $1.08M.
IMC Chicago first reported a position in ProShares Ultra NASDAQ Biotechnology in Q1 2023 and held it in 6 quarters.
IMC Chicago's ProShares Ultra NASDAQ Biotechnology position peaked at $2.43M in Q4 2023.
17 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q2 2025.

Based on IMC Chicago's 13F filing for Q2 2025, filed 22 Jul 2025.